DGAP-News: 4SC AG / Key word(s): Capital Increase/Miscellaneous Capital increase 4SC AG: subscription offer period ended, rump placement started 29.06.2012 / 10:32 --------------------------------------------------------------------- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS Press release 4SC AG capital increase: subscription offer period ended, rump placement started Planegg-Martinsried, 29 June 2012 - Biopharmaceuticals company 4SC AG (Frankfurt, Prime Standard: VSC) has announced that yesterday the subscription period in connection with the company's cash capital increase from authorized capital with subscription rights at a subscription price of EUR 1.50 ended. Prior to the commencement of the subscription offer Kempen & Co N.V., acting as sole global co-ordinator in the transaction, successfully placed 2,911,000 shares with institutional investors in selected countries, by way of a pre-placement, at a price of EUR 1.50 per share. As a result of the shares placed in the pre-placement and the subscription offer, gross proceeds amounting to EUR 10,779,766.50 have already been secured - subject to registration of the capital increase in the commercial register. Shares not subscribed under the subscription offer will today be offered to institutional investors in selected countries by way of a rump placement. The rump placement will start with immediate effect and books will close today. After closing of the books, the final results of the capital increase will be published. The company intends to raise proceeds of between EUR 10 million and EUR 15 million in total from the capital increase. A public offering of the new shares is not made. Additional information about the share capital increase of 4SC AG Under the capital increase, the company's current share capital of EUR 41,968,304 is set to be increased by way of a partial utilisation of the authorised capital by up to EUR 10,492,076.00 to an amount of up to EUR 52,460,380.00 through the issue of up to 10,492,076 new no-par value bearer shares, each representing a pro rata amount of the share capital of EUR 1.00 and having full dividend rights starting from 1 January 2012. The new shares are expected to be admitted for trade on the Frankfurt Stock Exchange in the third quarter of 2012 on the basis of a listing prospectus. However, shareholders who have exercised their subscription rights for new shares and institutional investors who have purchased new shares in the rump placement will receive delivery of existing 4SC AG shares already admitted for trade on the Frankfurt Stock Exchange (ISIN DE000573818) instead of new shares, subject to registration of the capital increase in the commercial register (Handelsregister). The existing shares required for this were being made available by an existing major shareholder by way of a further securities lending, in order to allow the shares to be immediately tradable by these shareholders or investors. Delivery of shares purchased by way of exercise of the subscription rights and in the rump placement is envisaged to take place on 4 July 2012. The proceeds from the capital increase shall primarily ensure the successful advancement of the company's existing clinical and preclinical development programmes. This includes preparing for - preferably together with pharma partners - a registration trial for the cancer drug resminostat for the treatment of advanced liver cancer (HCC) and a clinical Phase IIb trial with the drug candidate vidofludimus for the treatment of inflammatory bowel disease (IBD), speeding up and completing an ongoing Phase I/II trial with resminostat for the treatment of colorectal cancer, and completing Phase I studies with other 4SC anti-cancer agents Press release ends Legal Note This announcement does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for, securities to any person in Germany, the European Union, Australia, Canada, Japan, or the United States or in any jurisdiction in which such offer or solicitation is unlawful. The shares of the company have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the 'Securities Act'), and may not be offered, sold, delivered or otherwise transferred in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The offer and the sale of the shares of the company have not been, and will not be, registered under the applicable securities laws of Australia, Canada or Japan. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. There will be no public offer of the shares in Germany, elsewhere in the European Union or in the United States. This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order') or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as 'relevant persons'). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons. This announcement may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services, future financial results, or assumptions underlying or relating to any such statements, each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors. About 4SC The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 96 employees at the end of 2011. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005. For more information please visit www.4sc.com or contact: 4SC Jochen Orlowski, Corporate Communications & Investor Relations jochen.orlowski(at)4sc.com, Tel.: +49 (0)89 70 07 63 66 MC Services Raimund Gabriel raimund.gabriel(at)mc-services.eu, Tel.: +49 (0)89 21 02 28 30 End of Corporate News --------------------------------------------------------------------- 29.06.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: 4SC AG Am Klopferspitz 19a 82152 Martinsried Germany Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 E-mail: public@4sc.com Internet: www.4sc.de ISIN: DE0005753818 WKN: 575381 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 175870 29.06.2012
DGAP-News: Capital increase 4SC AG: subscription offer period ended, rump placement started
| Source: EQS Group AG